Synopsis Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. The objective of this study was to investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox–Gastaut syndrome, a severe developmental epileptic encephalopathy. This week’s “MED FACT” discusses a clinical trial from The New England Journal of Medicine, “Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome”.
Authors: Orrin Devinsky et. al., Key Takeaways: Cannabidiol at a dose of 10 or 20 mg/kg/day resulted in reduction in the frequency of drop seizures. Objective: To determining the efficacy and safety of cannabidiol to treat drop seizures Study Type: Double-blind, placebo-controlled trial Participants: 225 What Was The Need For This Study Cannabidiol has…
